1. A 42-year-old woman with heterozygous familial hypercholesterolemia (HeFH) confirmed by genetic testing has been on rosuvastatin 40 mg daily plus ezetimibe 10 mg daily for 18 months. Her most recent fasting LDL-C is 118 mg/dL. She has no established atherosclerotic cardiovascular disease (ASCVD) but has a DLCN (Dutch Lipid Clinic Network) score of 9, placing her in the "definite FH" category. Her 10-year ASCVD risk is estimated at 14%. Her cardiologist reviews her treatment options. Which of the following represents the most appropriate next step in her lipid management?
A) Switch rosuvastatin to atorvastatin 80 mg daily, as this high-intensity statin produces greater LDL-C reduction than rosuvastatin 40 mg and may allow her to reach target without adding a third agent.
B) Add niacin 1,500 mg extended-release daily to her current regimen, as niacin lowers LDL-C through inhibition of hepatic VLDL synthesis and is the appropriate third-line agent in FH patients not at target on statin plus ezetimibe.
C) Add evolocumab or alirocumab to her current statin plus ezetimibe regimen, as PCSK9 inhibitors (proprotein convertase subtilisin/kexin type 9 inhibitors) are the guideline-endorsed third agent in HeFH patients with LDL-C above target on dual oral therapy.
D) Refer for lipoprotein apheresis, as this is the standard next intervention for any HeFH patient with LDL-C above 100 mg/dL who has failed dual oral therapy.
E) Continue current therapy and recheck LDL-C in 12 months, as the ACC/AHA guideline does not recommend a target below 130 mg/dL for primary prevention HeFH patients without established ASCVD.
ANSWER: C
Rationale:
In heterozygous familial hypercholesterolemia (HeFH), the LDL-C treatment target for patients without established ASCVD is below 100 mg/dL per ACC/AHA guidelines and below 100 mg/dL (moderate risk) or below 70 mg/dL (high risk) per ESC/EAS guidelines. This patient, with a DLCN score of 9 ("definite FH") and a 10-year ASCVD risk of 14%, clearly has not reached target on maximally tolerated statin plus ezetimibe — a combination that typically achieves 60 to 65% LDL-C reduction but is often insufficient when baseline LDL-C is 190 to 350 mg/dL, as is characteristic of HeFH. PCSK9 inhibitors — specifically evolocumab and alirocumab — are the guideline-endorsed third agent in this setting. Both are FDA-approved for HeFH and produce an additional 55 to 70% LDL-C reduction on background statin plus ezetimibe by preventing PCSK9-mediated lysosomal degradation of LDL receptors, thereby increasing steady-state receptor density at the hepatocyte surface and amplifying LDL clearance through the residual functional receptor pool.
Option A: Option A is incorrect: rosuvastatin 40 mg and atorvastatin 80 mg are both high-intensity statins producing comparable LDL-C reductions of approximately 50 to 55%; switching between them adds minimal incremental benefit and does not constitute appropriate escalation in a patient who has already reached maximal statin intensity.
Option B: Option B is incorrect: niacin has not demonstrated cardiovascular outcomes benefit when added to statin therapy (AIM-HIGH, HPS2-THRIVE), and its use as a third-line lipid-lowering agent in HeFH is not guideline-endorsed; it has largely been displaced by PCSK9 inhibitors for residual LDL-C lowering.
Option D: Option D is incorrect: lipoprotein apheresis is reserved for HeFH patients with established ASCVD or HoFH patients not adequately controlled on maximally tolerated pharmacological therapy — it is not the next step after dual oral therapy failure in a primary prevention HeFH patient without recurrent events.
Option E: Option E is incorrect: a target of below 130 mg/dL is not the standard for HeFH; both ACC/AHA and ESC/EAS guidelines endorse more aggressive targets for FH, and continuing without escalation at LDL-C 118 mg/dL in a patient with definite FH and elevated 10-year risk is clinically inappropriate.
2. A 58-year-old man is admitted to the coronary care unit with an ST-elevation myocardial infarction (STEMI) and undergoes primary percutaneous coronary intervention (PCI). He has no prior history of cardiovascular disease and was not on any lipid-lowering therapy before admission. A fasting lipid panel drawn 6 days after admission shows LDL-C of 74 mg/dL, HDL-C 42 mg/dL, and triglycerides 148 mg/dL. A cardiology fellow reviewing the case suggests that since the LDL-C is already below 70 mg/dL, no statin therapy is needed at discharge and a repeat lipid panel in 6 months would be appropriate. Which of the following most accurately identifies the error in this reasoning?
A) The lipid panel drawn 6 days post-MI underestimates the patient's true chronic LDL-C because the systemic inflammatory response of acute myocardial infarction suppresses LDL-C by 30 to 40% within the first several days; the true baseline LDL-C is likely substantially higher, and high-intensity statin should be initiated regardless of the admission or in-hospital lipid value.
B) The fellow's reasoning is correct regarding the LDL-C value but incorrect about timing; the statin should still be started in-hospital because early initiation within 24 hours of PCI produces direct anti-restenotic effects on the coronary endothelium that are independent of LDL-C lowering.
C) The fellow is incorrect because post-ACS patients require an LDL-C target below 55 mg/dL per ACC/AHA guidelines, and a value of 74 mg/dL — even if accurate — does not meet this mandatory threshold; statin initiation is therefore still required.
D) The fellow's reasoning correctly identifies that a measured LDL-C below 70 mg/dL during hospitalization eliminates the need for statin initiation, but errs in the follow-up interval — a repeat lipid panel at 6 weeks rather than 6 months is the appropriate post-discharge monitoring strategy.
E) The fellow is incorrect because statin therapy is indicated in all post-ACS patients regardless of LDL-C level due to mandatory secondary prevention requirements encoded in hospital discharge quality metrics and Joint Commission core measures.
ANSWER: A
Rationale:
The critical pharmacological and physiological principle here is that acute myocardial infarction triggers a systemic inflammatory response that transiently suppresses circulating LDL-C by approximately 30 to 40% within the first 24 to 96 hours, a well-characterized phenomenon mediated in part by acute-phase reactant effects on lipoprotein metabolism and redistributive fluid shifts. A lipid panel drawn 6 days post-MI therefore substantially underestimates the patient's true pre-event chronic LDL-C. In this case, a measured LDL-C of 74 mg/dL likely reflects a true baseline of approximately 105 to 120 mg/dL — a level that clearly warrants high-intensity statin therapy. The clinical implication is that the pre-treatment lipid panel should ideally be drawn within 24 to 72 hours of presentation (before the nadir of acute LDL-C suppression) to capture the most accurate baseline; this value is essential for calculating percentage reduction targets and anticipating whether add-on therapy will be needed. Crucially, high-intensity statin therapy is indicated in all post-ACS patients regardless of the LDL-C value — both for LDL-C lowering and for pleiotropic benefits including plaque stabilization and endothelial function improvement that occur before significant lipid changes are measurable.
Option B: Option B is incorrect in its mechanism: while early statin initiation is indeed recommended, the primary evidence base is not anti-restenotic endothelial effects specifically within 24 hours of PCI; the broader pleiotropic and lipid-lowering rationale governs the recommendation.
Option C: Option C is incorrect: the ACC/AHA 2018 guideline primary target for very high-risk secondary prevention is below 70 mg/dL (with a Class IIa option for below 55 mg/dL in extreme risk); below 55 mg/dL is the ESC/EAS 2019 guideline target — misattributing it as the ACC/AHA mandatory threshold is inaccurate.
Option D: Option D is incorrect: this option accepts the validity of the in-hospital LDL-C as a true reflection of chronic LDL-C, which is the core error; the suppressed in-hospital value cannot be used to make a determination that statin therapy is unnecessary.
Option E: Option E is incorrect: while discharge statin prescribing is a quality metric, the pharmacological rationale — not regulatory compliance — is the correct basis for the clinical decision, and this answer does not address the key error in the fellow's reasoning about the suppressed LDL-C value.
3. A 16-year-old boy with homozygous familial hypercholesterolemia (HoFH) confirmed by genetic testing carries two null mutations in the LDL receptor (LDLR) gene, resulting in complete absence of functional LDL receptor protein. His LDL-C on maximally tolerated rosuvastatin 40 mg plus ezetimibe 10 mg plus evolocumab 420 mg monthly is 410 mg/dL — a reduction of only 12% from pretreatment baseline. His lipid specialist considers additional therapy. Which of the following best explains why evinacumab would be expected to produce meaningful LDL-C reduction in this patient when evolocumab has produced negligible benefit?
A) Evinacumab acts downstream of the LDL receptor by inhibiting hepatic cholesterol esterification via ACAT (acyl-CoA:cholesterol acyltransferase) inhibition, reducing intracellular cholesterol storage and thereby upregulating alternative LDL clearance receptors including LRP1 and VLDLR that are unaffected by LDLR mutations.
B) Evinacumab inhibits PCSK9 through a distinct epitope that allows receptor recycling even in the absence of functional LDLR, restoring partial LDL clearance through a compensatory LDLR-homologous protein expressed at higher levels in receptor-negative HoFH.
C) Evinacumab reduces LDL-C by blocking intestinal cholesterol absorption via NPC1L1 (Niemann-Pick C1-like 1) inhibition, a mechanism entirely independent of hepatic LDL receptor expression; because intestinal absorption contributes approximately 40% of circulating LDL-C, this produces clinically meaningful LDL-C reduction regardless of LDLR genotype.
D) Evinacumab inhibits ANGPTL3 (angiopoietin-like protein 3), an endogenous inhibitor of both lipoprotein lipase and endothelial lipase; ANGPTL3 inhibition enhances triglyceride-rich lipoprotein clearance and reduces hepatic VLDL production through a mechanism entirely independent of LDL receptor expression, thereby lowering LDL-C even in patients with no functional LDLR.
E) Evinacumab activates hepatic LXR (liver X receptor) signaling, upregulating the ABCA1 and ABCG5/G8 transporters that mediate reverse cholesterol transport and biliary cholesterol excretion; this bypass pathway removes cholesterol from the circulation without requiring LDL receptor-mediated endocytosis.
ANSWER: D
Rationale:
The key pharmacological distinction in this question is the LDL receptor-independence of evinacumab versus the LDL receptor-dependence of statins, ezetimibe, and PCSK9 inhibitors. In receptor-negative HoFH — where both LDLR alleles carry null mutations and no functional receptor protein is produced — statins (which upregulate LDL receptor expression via SREBP-2 activation) and PCSK9 inhibitors (which preserve LDL receptor recycling by blocking PCSK9-mediated lysosomal targeting) both operate through mechanisms that require at least some functional LDL receptor; in the complete absence of LDLR protein, neither drug class can meaningfully lower LDL-C. Evinacumab is a fully human monoclonal antibody targeting ANGPTL3 (angiopoietin-like protein 3), an endogenous inhibitor of both lipoprotein lipase (LPL) and endothelial lipase. ANGPTL3 normally inhibits LPL, reducing the catabolism of triglyceride-rich lipoproteins (VLDL, chylomicrons); it also inhibits endothelial lipase, reducing HDL-C clearance. By neutralizing ANGPTL3, evinacumab enhances LPL-mediated triglyceride-rich lipoprotein hydrolysis and reduces hepatic VLDL production through mechanisms that operate entirely upstream of and independent from LDL receptor pathways. The downstream effect of enhanced VLDL catabolism is a reduction in the flux of IDL and LDL particles derived from VLDL — lowering LDL-C by reducing precursor particle input rather than by enhancing LDL clearance via receptor-mediated endocytosis. In the pivotal trial in HoFH patients, evinacumab 15 mg/kg IV every 4 weeks produced approximately 47% LDL-C reduction from baseline, including in patients with no residual LDLR function.
Option A: Option A is incorrect: evinacumab does not act via ACAT inhibition; ACAT inhibitors have been investigated as lipid-lowering agents but have not demonstrated clinical cardiovascular benefit and are not the mechanism of evinacumab.
Option B: Option B is incorrect: evinacumab does not target PCSK9 at any epitope; it targets ANGPTL3, a structurally and functionally unrelated protein.
Option C: Option C is incorrect: NPC1L1 inhibition is the mechanism of ezetimibe, not evinacumab; furthermore, even complete NPC1L1 blockade eliminates only intestinal cholesterol absorption and does not reduce VLDL-derived LDL production, making this insufficient for the profound LDL-C reduction required in HoFH.
Option E: Option E is incorrect: evinacumab does not activate LXR signaling or ABCA1/ABCG5/G8 transporters; LXR agonism has been investigated pharmacologically but is not the mechanism of any approved lipid-lowering agent.
4. A 67-year-old man with no prior history of coronary artery disease, myocardial infarction, or stroke presents with new-onset dyspnea and is found to have non-ischemic dilated cardiomyopathy with a left ventricular ejection fraction (LVEF) of 32% on echocardiography. Workup including coronary angiography confirms no obstructive coronary artery disease. His fasting LDL-C is 128 mg/dL. His cardiologist considers initiating high-intensity statin therapy, reasoning that elevated LDL-C and potential pleiotropic statin benefits — reduced inflammation, improved endothelial function, anti-arrhythmic effects — might slow HF progression or reduce mortality. Which of the following most accurately characterizes the evidence-based approach to this clinical question?
A) High-intensity statin therapy should be initiated because the CORONA trial demonstrated that rosuvastatin 10 mg reduced the primary composite endpoint of cardiovascular death, non-fatal MI, and non-fatal stroke in patients with chronic heart failure with reduced ejection fraction (HFrEF), establishing statin therapy as guideline-endorsed for HF outcomes.
B) Statin therapy should not be initiated solely for HF outcomes in this patient; both CORONA and GISSI-HF demonstrated no reduction in primary cardiovascular endpoints in chronic HFrEF, and current ACC/AHA and ESC heart failure guidelines do not recommend initiating statins de novo for HF-specific outcomes in the absence of a concurrent ASCVD indication.
C) Statin therapy is not recommended in non-ischemic cardiomyopathy specifically because statins inhibit mitochondrial coenzyme Q10 (ubiquinone) synthesis through HMG-CoA reductase inhibition in cardiac myocytes, which may worsen myocardial energetics in the already-failing non-ischemic heart — an effect not relevant in ischemic HF where mitochondrial dysfunction is already established.
D) High-intensity statin should be initiated because the patient's LDL-C of 128 mg/dL exceeds the 70 mg/dL threshold that triggers mandatory statin therapy per ACC/AHA primary prevention guidelines regardless of HF status, and the presence of HF does not modify this threshold.
E) Moderate-intensity statin therapy — but not high-intensity — is appropriate in this patient; the GISSI-HF trial used rosuvastatin 10 mg (moderate intensity) and showed a trend toward benefit that did not reach significance, suggesting the dose was insufficient and that high-intensity therapy might have produced a positive result.
ANSWER: B
Rationale:
This question addresses one of the most clinically important negative trial findings in cardiovascular pharmacology. The theoretical rationale for statin therapy in heart failure — pleiotropic benefits including anti-inflammatory, endothelial-protective, and anti-arrhythmic effects — generated substantial enthusiasm before the landmark randomized trials reported. CORONA (2007) enrolled 5,011 patients with ischemic HFrEF (LVEF ≤40%, NYHA class II–IV) and randomized them to rosuvastatin 10 mg or placebo; despite reducing LDL-C by 45% and CRP by 37%, rosuvastatin did not reduce the primary composite of cardiovascular death, non-fatal MI, or non-fatal stroke (HR 0.92; p=0.12). GISSI-HF (2008) enrolled 4,574 patients with chronic HF of any etiology (including non-ischemic) and found no significant reduction in either primary endpoint — all-cause mortality or the composite of all-cause mortality plus cardiovascular hospitalization. Both trials establish that statin therapy does not improve HF-specific outcomes, and current ACC/AHA and ESC heart failure guidelines do not recommend initiating statins de novo for HF outcomes in patients without a concurrent ASCVD indication. This patient has non-ischemic cardiomyopathy and no established ASCVD — there is no secondary prevention indication, and no evidence-supported primary prevention benefit specific to his HF. If he had concurrent established ASCVD (prior MI, stroke, PAD), continuing or initiating statin therapy for ASCVD secondary prevention would be appropriate — and the HF would not negate that indication.
Option A: Option A is incorrect: CORONA did not demonstrate a reduction in the primary composite endpoint; the p-value was 0.12, and the trial is cited as a negative trial. A significant reduction in hospitalizations for cardiovascular causes was observed as a secondary endpoint only.
Option C: Option C is incorrect: while statin-associated inhibition of the mevalonate pathway reduces coenzyme Q10 synthesis, the clinical significance of this effect in heart failure remains unproven and this is not the basis for current guideline recommendations against statin initiation in HF.
Option D: Option D is incorrect: the ACC/AHA primary prevention framework does not establish a mandatory LDL-C threshold of 70 mg/dL that universally triggers statin initiation; the decision is risk-based, and more importantly, HF context and absence of ASCVD indication are highly relevant to the treatment decision.
Option E: Option E is incorrect: GISSI-HF's neutral result is not attributed to insufficient statin dose; the trial was adequately powered and used a dose consistent with the trial design, and the negative result is interpreted as absence of HF-specific benefit rather than a dose inadequacy.
5. A 39-year-old man with poorly controlled type 2 diabetes (HbA1c 11.4%) and known hypertriglyceridemia presents to the emergency department with acute-onset epigastric pain radiating to the back, nausea, and vomiting. Serum lipase is 1,840 U/L. A fasting triglyceride (TG) level drawn on admission is 2,340 mg/dL. He is admitted for acute pancreatitis. In addition to IV fluid resuscitation and analgesia, which of the following most accurately describes the pharmacological management priority and its mechanistic rationale?
A) Administer fenofibrate 145 mg orally immediately; fenofibrate activates PPARalpha (peroxisome proliferator-activated receptor alpha), which upregulates lipoprotein lipase gene expression and increases VLDL catabolism, reducing triglycerides within 6 to 12 hours and representing first-line emergency pharmacological therapy for severe hypertriglyceridemia-induced pancreatitis.
B) Initiate high-intensity statin therapy with atorvastatin 80 mg immediately; while statins are not primarily triglyceride-lowering agents, they reduce hepatic VLDL synthesis through SREBP-2 suppression, and their rapid pleiotropic anti-inflammatory effects on pancreatic microcirculation reduce the severity of triglyceride-induced pancreatitis independent of triglyceride levels.
C) Administer volanesorsen subcutaneously; as an antisense oligonucleotide (ASO) targeting apoC-III (apolipoprotein C-III) mRNA, volanesorsen reduces triglycerides by 70 to 80% and is the FDA-approved first-line pharmacological agent for acute hypertriglyceridemia-induced pancreatitis at triglyceride levels above 1,000 mg/dL.
D) Initiate plasmapheresis immediately; triglyceride levels above 2,000 mg/dL represent an absolute indication for emergency plasmapheresis as the only intervention with sufficient speed of triglyceride reduction to prevent progression to necrotizing pancreatitis, and pharmacological agents are contraindicated until plasmapheresis reduces triglycerides below 500 mg/dL.
E) Initiate an insulin infusion in addition to fenofibrate and very low-fat dietary restriction; insulin activates lipoprotein lipase (LPL) — the primary enzyme responsible for triglyceride hydrolysis in VLDL and chylomicrons — and in the setting of severe diabetic hypertriglyceridemia, insulin-mediated LPL activation is a critical pharmacological mechanism for acute triglyceride reduction alongside dietary fat elimination.
ANSWER: E
Rationale:
This patient presents with severe hypertriglyceridemia-induced acute pancreatitis (triglycerides 2,340 mg/dL) in the setting of severely uncontrolled diabetes — a common precipitant because insulin resistance and relative insulin deficiency markedly impair LPL activity, causing reduced catabolism of triglyceride-rich lipoproteins (VLDL and chylomicrons) and massive hypertriglyceridemia. The mechanistic cornerstone of acute management in this specific scenario is insulin therapy: insulin is the primary physiological activator of LPL, the enzyme responsible for hydrolysis of triglycerides within circulating VLDL and chylomicrons at the endothelial surface. In diabetic hypertriglyceridemia, LPL activity is suppressed by insulin deficiency and insulin resistance; restoring insulin signaling rapidly upregulates LPL, accelerating TG catabolism. Concurrent management includes very low-fat dietary restriction (less than 15% of calories from fat, eliminating the chylomicron substrate) and fenofibrate initiation (which activates PPARalpha, further upregulating LPL gene transcription, increasing apoAV, and reducing apoC-III — a natural LPL inhibitor). Plasmapheresis is reserved for triglycerides above 2,000 to 3,000 mg/dL when organ-threatening pancreatitis is present and pharmacological measures are failing — it is not the mandatory first-line step and is not absolutely indicated at 2,340 mg/dL before attempting pharmacological therapy.
Option A: Option A is incorrect not because fenofibrate is wrong — it is appropriate — but because the option omits insulin therapy, which is mechanistically critical in the diabetic patient and is the most pharmacologically distinctive element of management in this scenario. A complete answer in this context requires insulin.
Option B: Option B is incorrect: statins are not indicated for acute hypertriglyceridemia management; their modest TG-lowering effect (10 to 15% via VLDL reduction) and onset time make them inappropriate as acute agents, and their role in acute pancreatitis beyond routine secondary prevention is not established.
Option C: Option C is incorrect: volanesorsen is FDA-approved for familial chylomicronemia syndrome (FCS), a specific monogenic disorder of LPL deficiency; it is not approved as a first-line acute agent for hypertriglyceridemia-induced pancreatitis in a patient with diabetic hypertriglyceridemia, and it requires weeks to achieve maximal TG lowering — not the rapid effect needed here.
Option D: Option D is incorrect: plasmapheresis is not absolutely indicated at triglycerides of 2,340 mg/dL before pharmacological measures are attempted; the threshold for plasmapheresis is generally 2,000 to 3,000 mg/dL with evidence of severe or progressing organ-threatening pancreatitis, and pharmacological therapy including insulin infusion, fenofibrate, and dietary fat restriction should be initiated concurrently as the initial approach.
6. A 54-year-old man with type 2 diabetes mellitus, hypertension, and no established ASCVD is seen in cardiology clinic for cardiovascular risk management. He is on atorvastatin 40 mg daily. His fasting lipid panel shows LDL-C 68 mg/dL, HDL-C 36 mg/dL, triglycerides 285 mg/dL, non-HDL-C 118 mg/dL, and apolipoprotein B (apoB) 96 mg/dL. His cardiologist notes that his LDL-C is at target but his non-HDL-C and apoB remain elevated. Which of the following best explains the clinical significance of the discordance between his LDL-C and apoB, and its therapeutic implications?
A) The discordance is clinically insignificant; non-HDL-C and apoB provide redundant information to LDL-C in diabetic patients, and guideline-endorsed treatment targets are defined exclusively by LDL-C — additional intensification of lipid-lowering therapy is not supported based on non-HDL-C or apoB values alone.
B) The elevated non-HDL-C reflects only the contribution of VLDL-C to atherogenic particle burden; this is entirely correctable by adding fenofibrate to reduce triglycerides, which will lower VLDL-C and thereby normalize non-HDL-C without requiring further LDL-C lowering.
C) In diabetic dyslipidemia, LDL-C systematically underestimates atherogenic particle burden because of a predominance of small, dense LDL particles and elevated triglyceride-rich remnant particles — each contributing to apoB and non-HDL-C without proportionally raising LDL-C; elevated apoB at apparent LDL-C target indicates residual atherogenic particle burden that warrants treatment intensification targeting non-HDL-C below 130 mg/dL and apoB below 80 mg/dL.
D) The discordance is explained entirely by the Friedewald equation underestimating LDL-C at triglyceride levels above 200 mg/dL; the patient's true LDL-C is approximately 118 mg/dL when calculated by the Martin/Hopkins method, and therapeutic decisions should be based on this corrected value rather than non-HDL-C or apoB.
E) Elevated apoB in the setting of normal LDL-C in a diabetic patient represents a spurious laboratory finding caused by glycosylation of apoB protein at elevated glucose concentrations, which alters its immunoreactivity in the assay; no treatment change is warranted until glycemic control is optimized and apoB is remeasured.
ANSWER: C
Rationale:
Type 2 diabetes produces a characteristic dyslipidemia driven by insulin resistance: elevated triglycerides (from increased hepatic VLDL secretion and reduced LPL activity), low HDL-C, and a shift in LDL particle composition toward small, dense particles. This phenotype creates a systematic discordance between measured LDL-C and atherogenic particle number: small, dense LDL particles contain less cholesterol per particle than large, buoyant LDL, meaning that a given apoB level (which reflects total atherogenic particle number — one apoB molecule per LDL, IDL, VLDL, and Lp(a) particle) corresponds to a higher particle count than in a non-diabetic patient at the same LDL-C. Additionally, elevated triglycerides drive accumulation of VLDL remnants and IDL particles — each carrying one apoB molecule and exerting atherogenic effects not captured by LDL-C measurement. Non-HDL-C (total cholesterol minus HDL-C) captures all cholesterol in apoB-containing particles including VLDL-C, IDL-C, and Lp(a)-C in addition to LDL-C, making it a more comprehensive atherogenic burden index. This patient's non-HDL-C of 118 mg/dL (ACC/AHA identifies non-HDL-C ≥130 mg/dL as an ASCVD risk enhancer; ESC non-HDL-C target for high-risk patients is below 100 mg/dL) and apoB of 96 mg/dL (ESC target for high-risk patients: below 80 mg/dL) indicate residual atherogenic burden that warrants consideration of therapy intensification — despite LDL-C appearing at target.
Option A: Option A is incorrect: current ACC/AHA and ESC guidelines explicitly endorse non-HDL-C and apoB as co-primary or secondary treatment targets in high-risk patients, particularly in diabetic dyslipidemia where LDL-C is acknowledged to underestimate atherogenic particle burden.
Option B: Option B is incorrect: while fenofibrate reduces VLDL-C and triglycerides, it does not address the LDL particle composition phenotype or the small, dense LDL particle count; moreover, fibrates do not reduce cardiovascular events when added to statins in this clinical context (ACCORD Lipid, PROMINENT), so fenofibrate alone is not the appropriate therapeutic response to this discordance pattern.
Option D: Option D is incorrect: while it is true that the Friedewald equation underestimates LDL-C at triglycerides above 200 to 400 mg/dL and the Martin/Hopkins equation performs better at high triglycerides, this alone does not explain the full discordance between LDL-C and apoB, and the clinical point of the question is the mechanistic basis of diabetic dyslipidemia's atherogenic particle pattern — not a calculation correction.
Option E: Option E is incorrect: glycosylation of apoB does not produce clinically significant assay interference with modern immunoturbidimetric apoB assays; this option describes a non-existent artifact.
7. A 72-year-old woman with stage 4 chronic kidney disease (CKD; estimated GFR 18 mL/min/1.73m²), established coronary artery disease, and hyperlipidemia is being seen by her nephrologist for medication optimization. She is currently on rosuvastatin 40 mg daily, which was started by her cardiologist before her CKD progressed. Her LDL-C is 58 mg/dL on this regimen. Her nephrologist recommends switching to atorvastatin 40 mg daily and capping any future rosuvastatin use at 10 mg in this population. The patient asks why the two statins are managed differently in CKD. Which of the following best explains the pharmacokinetic basis for this recommendation?
A) Rosuvastatin is a prodrug that requires renal hydroxylation to its active metabolite; in severe CKD, this activation step is impaired, reducing drug efficacy and requiring dose reduction to avoid accumulation of the inactive parent compound, which has direct nephrotoxic effects at high plasma concentrations.
B) Both rosuvastatin and atorvastatin undergo significant renal elimination, but rosuvastatin's elimination is more dependent on active tubular secretion via OAT3 (organic anion transporter 3); in CKD, OAT3 expression is downregulated, causing rosuvastatin accumulation specifically through this transporter-dependent pathway.
C) Atorvastatin is more water-soluble than rosuvastatin and therefore does not penetrate skeletal muscle cells, eliminating the risk of statin-associated myopathy (SAMS) in CKD patients where muscle toxicity risk is heightened; rosuvastatin's higher lipophilicity drives muscle uptake and myopathy at lower plasma concentrations.
D) Rosuvastatin undergoes substantially greater renal elimination than atorvastatin — approximately 28% is excreted unchanged in urine, and plasma concentrations increase significantly in severe CKD; the rosuvastatin prescribing label recommends a maximum dose of 10 mg/day in severe CKD and ESRD. Atorvastatin, by contrast, undergoes less than 2% renal excretion unchanged, is primarily hepatically metabolized via CYP3A4, and does not require dose adjustment for CKD.
E) Rosuvastatin and atorvastatin are equally renally eliminated, but rosuvastatin has a narrower therapeutic index in CKD because it produces a greater degree of HMG-CoA reductase inhibition per unit drug concentration in uremic muscle tissue, amplifying myopathy risk at standard doses; atorvastatin's lower intrinsic potency per molecule makes it safer at equivalent LDL-C lowering doses in this population.
ANSWER: D
Rationale:
The pharmacokinetic distinction between rosuvastatin and atorvastatin in chronic kidney disease is rooted in their differing routes of elimination. Rosuvastatin is a relatively hydrophilic statin that is not extensively metabolized by CYP enzymes — approximately 10% undergoes CYP2C9-mediated metabolism — and approximately 28% is excreted unchanged in the urine via active tubular secretion. In patients with severe CKD (estimated GFR below 30 mL/min/1.73m²) and end-stage kidney disease, this renal excretion pathway is markedly impaired, leading to substantially increased rosuvastatin plasma concentrations — clinical pharmacokinetic studies have demonstrated AUC increases of 3-fold or greater in severe renal impairment. The rosuvastatin prescribing label explicitly recommends against doses above 10 mg/day in patients with severe CKD and in end-stage kidney disease, and recommends initiating at 5 mg/day in this population due to the myopathy risk from elevated plasma drug levels. Atorvastatin, by contrast, is predominantly eliminated via hepatic metabolism through CYP3A4, with less than 2% excreted unchanged in urine; it does not require dose adjustment for CKD and is generally the preferred high-intensity statin in the CKD population. The clinical implication is straightforward: this patient's current rosuvastatin 40 mg dose in the setting of estimated GFR 18 mL/min/1.73m² represents a substantially supra-recommended exposure and carries meaningful myopathy risk; switching to atorvastatin with its hepatic elimination profile is pharmacokinetically rational and guideline-consistent.
Option A: Option A is incorrect: rosuvastatin is not a prodrug requiring renal activation; it is administered as the active acid form and does not require biotransformation for pharmacological activity.
Option B: Option B is incorrect: while rosuvastatin does undergo some transporter-mediated hepatic uptake (OATP1B1, OATP1B3) and renal excretion, the explanation of OAT3 downregulation as the specific mechanism of accumulation is not established in the prescribing label rationale; the pharmacokinetic basis is simply the proportion of unchanged drug excreted renally combined with reduced GFR.
Option C: Option C is incorrect: atorvastatin is actually more lipophilic than rosuvastatin, not less; the lipophilicity comparison is inverted in this option, and moreover, the myopathy risk in CKD is driven by elevated systemic drug exposure from impaired elimination rather than lipophilicity-driven muscle penetration differences.
Option E: Option E is incorrect: rosuvastatin and atorvastatin are not equally renally eliminated — this is the core pharmacokinetic fact the question tests — and the concept of differential HMG-CoA reductase inhibition potency per molecule in uremic muscle tissue is not a recognized pharmacological mechanism.
8. A 63-year-old man with established coronary artery disease and type 2 diabetes is on rosuvastatin 40 mg daily with an LDL-C of 61 mg/dL. His fasting triglycerides are 178 mg/dL on his most recent panel, drawn after 3 months of dietary modification. His cardiologist is considering adding icosapentaenoic acid ethyl ester (IPE) 4 g/day for residual cardiovascular risk reduction. A cardiology fellow reviewing the case states that this patient does not meet REDUCE-IT trial eligibility criteria because his triglycerides of 178 mg/dL are below the minimum threshold of 200 mg/dL used in that trial. Which of the following most accurately evaluates the fellow's statement?
A) The fellow is incorrect; the REDUCE-IT trial enrolled patients with fasting triglycerides of 135 to 499 mg/dL, and this patient's triglyceride level of 178 mg/dL falls within the enrollment window; ACC/AHA guidelines endorse IPE 4 g/day as a Class IIa recommendation for patients in this triglyceride range with established ASCVD or diabetes on statin therapy.
B) The fellow is correct; REDUCE-IT enrolled patients with triglycerides of 200 to 499 mg/dL and excluded patients with triglycerides below 200 mg/dL; IPE therapy is not guideline-endorsed below this threshold, and adding IPE at a triglyceride level of 178 mg/dL would be outside the trial-supported range.
C) The fellow is correct that the patient does not meet REDUCE-IT eligibility, but the correct minimum threshold is 150 mg/dL, not 200 mg/dL; the fellow has the right clinical conclusion but cites an incorrect threshold — IPE is not indicated below 150 mg/dL regardless of ASCVD status.
D) The fellow's statement about trial eligibility is irrelevant because IPE 4 g/day is FDA-approved for all patients with fasting triglycerides above 100 mg/dL on background statin therapy; guideline and trial eligibility criteria do not restrict prescribing, and the clinical decision is driven by FDA label indications rather than trial enrollment criteria.
E) The fellow is correct that this patient does not meet REDUCE-IT criteria, and IPE should not be added; however, the appropriate alternative is to intensify triglyceride lowering with fenofibrate until triglycerides exceed 200 mg/dL, at which point REDUCE-IT criteria would be met and IPE could be initiated.
ANSWER: A
Rationale:
The REDUCE-IT (Reduction of Cardiovascular Events with Icosapentaenoic Acid-Intervention Trial) trial enrolled patients with established ASCVD or diabetes plus at least one additional cardiovascular risk factor who were on stable statin therapy with fasting triglycerides of 135 to 499 mg/dL — not 200 to 499 mg/dL as the fellow states. The lower enrollment threshold of 135 mg/dL was deliberately chosen to capture the broad population of statin-treated patients with residual hypertriglyceridemia, including those in the borderline-high range. This patient's triglycerides of 178 mg/dL fall within the 135 to 499 mg/dL REDUCE-IT enrollment window, he has established coronary artery disease (ASCVD), is on background statin therapy with adequate LDL-C control, and has type 2 diabetes — he meets the trial's eligibility profile precisely. The ACC/AHA 2018 guideline updated with the REDUCE-IT evidence endorses IPE 4 g/day as a Class IIa recommendation for patients with established ASCVD or diabetes on statin therapy with triglycerides 135 to 499 mg/dL. IPE (icosapentaenoic acid ethyl ester) — a highly purified EPA-only formulation — reduced the primary composite cardiovascular endpoint by 25% relative risk reduction in REDUCE-IT (HR 0.75; 95% CI 0.68–0.83), with the benefit extending across the full triglyceride range, including the subgroup near the lower enrollment threshold.
Option B: Option B is incorrect: the minimum REDUCE-IT enrollment threshold was 135 mg/dL, not 200 mg/dL; this is a clinically important distinction that affects a large number of statin-treated patients with borderline-high triglycerides.
Option C: Option C is incorrect: the 150 mg/dL threshold does not correspond to any REDUCE-IT enrollment criterion; this is a fabricated threshold.
Option D: Option D is incorrect: IPE 4 g/day (Vascepa) is FDA-approved to reduce cardiovascular risk in adult patients with triglycerides ≥150 mg/dL who are on maximally tolerated statin therapy — not for all patients above 100 mg/dL; additionally, guideline evidence does matter for clinical decision-making, and FDA label indications do not simply override the evidence-based framework.
Option E: Option E is incorrect: the suggestion to use fenofibrate to elevate triglycerides to meet a threshold is pharmacologically absurd and clinically harmful; fibrates lower triglycerides and have not demonstrated cardiovascular event reduction in this context.
9. An 81-year-old woman with moderate vascular dementia, stage IV ovarian cancer on best supportive care, severe osteoporosis with two recent vertebral compression fractures, and hypertension presents to a geriatric medicine clinic for medication review. Her medication list includes atorvastatin 40 mg daily, which was initiated 9 years ago for primary prevention of cardiovascular disease. At that time her 10-year ASCVD risk was 16%. She has no history of myocardial infarction, stroke, coronary revascularization, or peripheral arterial disease. Her estimated life expectancy is 8 to 12 months. Her current LDL-C is 72 mg/dL. Her family asks whether continuing the statin is appropriate. Which of the following most accurately characterizes the evidence-based approach to this patient's statin therapy?
A) Continue atorvastatin 40 mg without modification; the ACC/AHA primary prevention guideline endorses statin therapy for all patients with a calculated 10-year ASCVD risk above 10% regardless of age or life expectancy, and discontinuation in a patient with LDL-C at target would increase her short-term cardiovascular event risk.
B) Switch to rosuvastatin 20 mg daily; this moderate-intensity statin maintains adequate LDL-C control while reducing pill burden compared to high-intensity atorvastatin, and represents the appropriate dose adjustment in elderly patients with limited life expectancy per ACC/AHA geriatric prescribing guidance.
C) Continue the statin but add ezetimibe 10 mg to achieve LDL-C below 55 mg/dL; at age 81 with active cancer, maximizing LDL-C control reduces the competing-risk contribution of cardiovascular events to her overall mortality, improving quality-adjusted life expectancy.
D) Discontinue atorvastatin; this patient is a strong candidate for statin deprescribing — she is on primary prevention therapy, has an estimated life expectancy of 8 to 12 months that is shorter than the estimated 2 to 5 year time-to-benefit horizon for primary prevention statins, and evidence from the OPTIMIZE trial supports the safety of statin discontinuation in patients with limited life expectancy on primary prevention statins, with no significant excess of cardiovascular events and improvement in quality of life measures.
E) Discontinue atorvastatin only after a shared decision-making conversation in which the patient demonstrates capacity to understand the cardiovascular risk of discontinuation; if the patient lacks capacity due to vascular dementia, the statin must be continued per surrogate decision-making principles until a formal ethics consultation is completed.
ANSWER: D
Rationale:
This patient is a textbook candidate for evidence-based statin deprescribing. The clinical framework for deprescribing in the elderly integrates several key factors: indication (primary vs. secondary prevention), estimated life expectancy relative to the time-to-benefit horizon of statin therapy, frailty and comorbidity burden, and patient preferences. This patient is on primary prevention therapy — she has never had an atherosclerotic cardiovascular disease event. The estimated time-to-benefit for primary prevention statins is approximately 2 to 5 years — the period over which risk reduction accumulates to a clinically meaningful magnitude. Her estimated life expectancy of 8 to 12 months is shorter than this horizon, meaning she is statistically unlikely to live long enough to accrue the cardiovascular benefit for which the statin was prescribed. The OPTIMIZE trial (2021), a cluster-randomized trial of statin discontinuation in patients ≥75 years with limited life expectancy (≤2 years by clinical estimate) on primary prevention statins, demonstrated that discontinuation was safe, reduced pill burden, and improved quality of life measures without a significant excess of major cardiovascular events over 12 months follow-up. Advanced cancer with a life expectancy below 12 months, severe dementia, and frailty with recent fractures further shift the benefit-risk calculus decisively toward deprescribing in this case.
Option A: Option A is incorrect: the ACC/AHA primary prevention guideline does not mandate statin continuation regardless of life expectancy; shared decision-making and individual patient factors — including life expectancy, frailty, and comorbidity — are explicitly incorporated into the guideline framework for patients ≥75 years.
Option B: Option B is incorrect: dose reduction to a moderate-intensity statin is not the appropriate response when the indication for the statin (primary prevention with meaningful life expectancy) no longer applies; this option preserves the medication burden without addressing the fundamental question of whether continued statin therapy serves the patient's goals.
Option C: Option C is incorrect: adding ezetimibe to intensify LDL-C lowering in a patient with 8 to 12 months estimated life expectancy and no established ASCVD is not evidence-supported and increases pill burden without plausible benefit within the patient's expected lifespan.
Option E: Option E is incorrect: shared decision-making is always appropriate, but the requirement for a formal ethics consultation before discontinuing a primary prevention medication in a patient who lacks capacity is not a standard clinical requirement and would introduce an unnecessary barrier to evidence-based deprescribing.
10. A 55-year-old man is admitted for a non-ST-elevation myocardial infarction (NSTEMI) and undergoes coronary stenting. A fasting lipid panel drawn within 24 hours of admission shows LDL-C 138 mg/dL. He is started on atorvastatin 80 mg daily before discharge. At his 6-week follow-up visit, his LDL-C is 88 mg/dL on high-intensity statin monotherapy. His cardiologist considers next steps. A cardiology fellow suggests the standard sequential approach: add ezetimibe now, recheck LDL-C in 6 weeks, and add a PCSK9 inhibitor (proprotein convertase subtilisin/kexin type 9 inhibitor) only if still above target after ezetimibe. The attending responds that in this patient, there is a specific evidence-based justification for proceeding directly to a PCSK9 inhibitor without first trialing ezetimibe. Which of the following best identifies that justification?
A) Early PCSK9 inhibitor initiation is justified because the IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) trial demonstrated that ezetimibe added to statin therapy in post-ACS patients failed to produce any significant cardiovascular event reduction, establishing ezetimibe as an ineffective agent in this clinical context.
B) A pre-treatment LDL-C of 138 mg/dL in a post-ACS patient places this patient in the ODYSSEY OUTCOMES subgroup with baseline LDL-C at or above 100 mg/dL, in which alirocumab demonstrated the greatest absolute cardiovascular event reduction and all-cause mortality benefit — supporting direct escalation to PCSK9 inhibitor without first trialing ezetimibe in this high-LDL-C post-ACS subgroup.
C) The sequential approach is inappropriate because PCSK9 inhibitors are superior to ezetimibe in all post-ACS patients regardless of baseline LDL-C; the ACC/AHA 2022 updated guideline upgraded the PCSK9 inhibitor recommendation to Class I ahead of ezetimibe in all post-ACS patients, eliminating the need for sequential escalation.
D) Direct PCSK9 inhibitor initiation is justified because his current LDL-C of 88 mg/dL after high-intensity statin is above the ACC/AHA target of 70 mg/dL; at this level, ezetimibe's maximal 18 to 24% additional reduction would bring LDL-C to only approximately 67 to 72 mg/dL, which is marginally at or below target and therefore insufficient — only PCSK9 inhibitor therapy can reliably achieve the necessary LDL-C reduction.
E) The sequential approach is contraindicated in post-ACS patients with prior statin therapy before the index event; because this patient was presumably untreated before admission, however, sequential escalation beginning with ezetimibe is the appropriate approach per guidelines.
ANSWER: B
Rationale:
The ODYSSEY OUTCOMES trial enrolled patients with acute coronary syndrome within 1 to 12 months of the qualifying event who were on maximally tolerated statin therapy, and randomized them to alirocumab 75 to 150 mg every 2 weeks versus placebo. The overall trial demonstrated a 15% relative risk reduction in the primary composite of coronary heart disease death, non-fatal MI, ischemic stroke, or unstable angina requiring hospitalization (HR 0.85; 95% CI 0.78–0.93). Critically, a pre-specified subgroup analysis showed that the greatest absolute cardiovascular event reduction and the all-cause mortality benefit were concentrated in the approximately 40% of patients with baseline LDL-C at or above 100 mg/dL at randomization. This patient's pre-treatment admission LDL-C of 138 mg/dL — which, as discussed in the clinical module, best reflects the true chronic LDL-C before acute-phase suppression — places him squarely in this high-LDL-C post-ACS subgroup. The clinical implication is that in a post-ACS patient presenting with LDL-C ≥100 mg/dL, the sequential approach of adding ezetimibe first, waiting 6 weeks, then escalating to PCSK9 inhibitor if still above target introduces a delay in achieving aggressive LDL-C lowering in the highest-risk period after ACS — and the ODYSSEY OUTCOMES data provide a specific evidence-based rationale for earlier PCSK9 inhibitor initiation in this subgroup without mandatory prior ezetimibe trial.
Option A: Option A is incorrect: IMPROVE-IT demonstrated that ezetimibe added to simvastatin in post-ACS patients did produce a statistically significant reduction in the primary composite endpoint (HR 0.936; p=0.016) — ezetimibe is not ineffective in post-ACS patients; this is a factual error.
Option C: Option C is incorrect: the characterization of a 2022 ACC/AHA guideline upgrade placing PCSK9 inhibitors as Class I ahead of ezetimibe in all post-ACS patients regardless of LDL-C is not accurate; the current ACC/AHA framework maintains a sequential escalation approach as standard, with flexibility for earlier PCSK9 inhibitor use in specific high-risk subgroups.
Option D: Option D is incorrect: while the arithmetic in this option is approximately correct, the reasoning — that ezetimibe is insufficient because it might only barely achieve target — is not the guideline-endorsed or trial-based rationale for skipping ezetimibe; it is a post-hoc quantitative argument rather than the evidence basis from ODYSSEY OUTCOMES.
Option E: Option E is incorrect: the sequential escalation approach is not contraindicated based on prior statin use history; this condition is fabricated and does not correspond to any guideline recommendation.
11. A 28-year-old woman with homozygous familial hypercholesterolemia (HoFH) carries a compound heterozygous LDLR mutation with approximately 5% residual LDL receptor activity. She is on maximally tolerated rosuvastatin 40 mg, ezetimibe 10 mg, and evolocumab 420 mg monthly. Despite this regimen, her LDL-C remains at 280 mg/dL. She has bilateral tendon xanthomas and a carotid intima-media thickness indicating early subclinical atherosclerosis. Her lipid specialist considers adding lomitapide (Juxtapid). Which of the following most accurately explains why lomitapide produces meaningful LDL-C reduction in HoFH patients when the LDL receptor pathway is severely impaired?
A) Lomitapide is a PCSK9 inhibitor that acts through a distinct intracellular mechanism — rather than neutralizing circulating PCSK9 in plasma, it blocks the intracellular chaperone function of PCSK9 within hepatocytes before secretion, allowing the residual 5% of functional LDL receptor to recycle more efficiently than with extracellular PCSK9 inhibition.
B) Lomitapide activates PPARgamma (peroxisome proliferator-activated receptor gamma) in hepatocytes, redirecting cholesterol away from VLDL assembly and toward biliary excretion via the ABCG5/ABCG8 transporter pathway; this reduces hepatic cholesterol output independently of LDL receptor expression.
C) Lomitapide inhibits NPC1L1 (Niemann-Pick C1-like 1) at the hepatocyte canalicular membrane, blocking re-absorption of biliary cholesterol from the bile-canalicular interface and reducing hepatic cholesterol recycling; this mechanism is entirely post-absorptive and independent of LDL receptor expression or VLDL secretion.
D) Lomitapide inhibits HMGCR (HMG-CoA reductase) through a distinct allosteric binding site not targeted by statins, bypassing the statin resistance that develops in HoFH due to LDLR-mediated feedback upregulation of HMGCR; this produces additive cholesterol synthesis inhibition at a step upstream of all receptor-dependent clearance mechanisms.
E) Lomitapide inhibits MTP (microsomal triglyceride transfer protein), which is required for the assembly and secretion of apoB-containing lipoproteins — including VLDL in hepatocytes and chylomicrons in enterocytes — by transferring triglycerides and phospholipids onto nascent apoB during lipoprotein assembly; MTP inhibition reduces VLDL secretion and the downstream production of IDL and LDL particles independent of LDL receptor expression, lowering LDL-C through reduced particle input rather than enhanced clearance.
ANSWER: E
Rationale:
Lomitapide is an MTP (microsomal triglyceride transfer protein) inhibitor that acts through a mechanism entirely independent of the LDL receptor — making it one of only two approved therapies (along with evinacumab) that can produce meaningful LDL-C reduction in receptor-negative or severely receptor-deficient HoFH patients. MTP is a lipid transfer protein located in the endoplasmic reticulum lumen of hepatocytes and enterocytes that is essential for the assembly of apoB-containing lipoproteins. It transfers triglycerides, cholesterol esters, and phospholipids onto the nascent apoB polypeptide during co-translational lipidation in the endoplasmic reticulum — a process required for VLDL assembly in the liver and chylomicron assembly in the small intestine. Without MTP-mediated lipid transfer, apoB is not lipidated, cannot form stable lipoprotein particles, and is targeted for proteasomal degradation. Lomitapide, at doses of 5 to 60 mg/day, inhibits MTP, reducing hepatic VLDL secretion and thereby decreasing the flux of VLDL → IDL → LDL particles in the circulation. Because this mechanism operates entirely at the level of lipoprotein assembly and secretion — upstream of LDL receptor-mediated clearance — it is fully effective even when LDL receptor activity is negligible or absent. In HoFH clinical trials, lomitapide produced approximately 40 to 50% LDL-C reduction as add-on therapy. Its principal adverse effects are gastrointestinal (diarrhea, nausea, abdominal pain) from chylomicron synthesis inhibition in the intestine, and hepatic steatosis from the accumulation of triglycerides that cannot be packaged into VLDL — a manageable but important consideration requiring monitoring of hepatic transaminases and liver fat content.
Option A: Option A is incorrect: lomitapide is not a PCSK9 inhibitor of any kind — intracellular or extracellular; its target is MTP.
Option B: Option B is incorrect: lomitapide does not act via PPARgamma activation or ABCG5/ABCG8-mediated biliary excretion; these are distinct mechanisms not associated with lomitapide's pharmacology.
Option C: Option C is incorrect: NPC1L1 inhibition is the mechanism of ezetimibe, not lomitapide; furthermore, NPC1L1 at the hepatocyte canalicular membrane is a secondary absorption site, and this option conflates intestinal ezetimibe pharmacology with hepatic mechanisms.
Option D: Option D is incorrect: lomitapide does not inhibit HMG-CoA reductase; its mechanism is MTP inhibition, not cholesterol synthesis suppression; the concept of a statin-resistant allosteric HMGCR site in HoFH is not a recognized pharmacological entity.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.